A message from Stocks.News 
A Bold Oncology Play: How SHPH Is Targeting Unmet Needs in Cancer, Radiotherapy, and Precision Diagnostics. Cancer remains one of the most urgent global health challenges, and companies capable of delivering smarter, more effective therapies stand to play a critical role in the years ahead. Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) is focused on developing solutions that enhance radiation therapy—one of the most widely used cancer treatments—while expanding into precision diagnostics and targeted oncology therapeutics. This multi-pronged approach aligns with the growing shift toward personalized medicine and outcome-driven cancer care. SHPH’s lead candidate, Ropidoxuridine (IPdR), is designed to make radiation therapy more effective for patients with glioblastoma, while its pipeline of HDAC inhibitors and PSMA-B ligand programs targets additional high-need cancer indications, including prostate cancer. The PC-Rad Test further strengthens the company’s precision strategy by aiming to predict radiation therapy success before treatment begins. Importantly, IPdR has received Orphan Drug Designation from the U.S. Food and Drug Administration, which may provide marketing exclusivity upon first FDA approval for the treatment of glioblastoma. This designation highlights both the seriousness of the disease and the potential clinical importance of SHPH’s approach. While clinical and commercial outcomes are never guaranteed, SHPH appears well positioned to contribute meaningfully to oncology innovation as demand for advanced cancer solutions continues to grow. Take a closer look at what’s driving SHPH into the biotech spotlight for 2026. | 
